There is currently a portfolio of critical therapeutic targets in academic labs and a plethora of compounds in biopharmaceutical companies that hold the real potential for curing various types of childhood cancer.

Unfortunately, industry has not been interested in childhood cancer, meaning that the financial resources allocated to pediatric oncology research have been insufficient, primarily funded by philanthropy, and focused only on academia.

Pumping additional dollars into pediatric academic research might create more findings and publications, but it is unlikely to result in new pediatric drugs. Putting such resources into set up a framework for new pediatric drug R&D, would likely yield more new medicines.